A well-integrated and cohesive community can deliver a national strategy that accelerates the adoption of in silico trials and supports its uptake by the UK’s LifeSciences sector.
The strategy must be adapted to the specific challenges, drivers, and opportunities in the UK, and engage with international initiatives to achieve faster, safer, and more cost-effective innovation for patient benefit.
Complementary sources of scientific evidence and drive confidence in patient benefit, safety, and effectiveness
or computational medicine, is an emerging discipline devoted to quantitative approaches for understanding the mechanisms, diagnosis, and treatment of human disease through the systematic application of mathematics, engineering, and computational science.
A community driving innovation and growth for patient safety and benefit using in silico evidence and regulatory science
Rt Hon Sir Iain Duncan Smith MP, the Rt Hon Theresa Villiers MP, and George Freeman MP, The Taskforce on Innovation, Growth and Regulatory Reform
Lord Frost statement to the House of Lords on Brexit opportunities, Sep 16th 2021.
Coordinated by InnovateUK KTN and the Royal Academy of Engineering, in collaboration with Avicenna Alliance and the Virtual Human Physiological Institute, we work with trade organisations, regulators, standardisation bodies and UK government.